Ozempic & GLP-1 Lawsuit (2026): Claims, Status & Who May Qualify

Ozempic, Wegovy, Mounjaro, and other GLP-1 receptor agonist drugs are at the center of product liability claims alleging that they caused severe gastrointestinal injuries, including stomach paralysis and intestinal obstruction. These claims are centralized in a federal multidistrict litigation, and as of June 2026 the litigation remains active and the underlying science is still developing. This page explains the claims, the science, and the current status neutrally.

This page is part of our Mass Tort & Product Liability overview.

What GLP-1 drugs are and the alleged harm

Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, are a class of prescription medicines used to treat type 2 diabetes and, in some formulations, to support weight loss. They include semaglutide, sold as Ozempic, Wegovy, and Rybelsus by Novo Nordisk, and tirzepatide and dulaglutide, sold as Mounjaro, Zepbound, and Trulicity by Eli Lilly. The drugs work in part by slowing how quickly the stomach empties. The lawsuits allege that this and related effects caused severe gastrointestinal injuries, most commonly gastroparesis, often described as stomach paralysis, along with ileus and intestinal obstruction, and that the manufacturers did not adequately warn patients and prescribers. A separate set of claims alleges a vision condition and is being handled in its own proceeding. These are descriptions of the allegations, not a finding that any GLP-1 drug caused any individual person's injury.

Note: These are allegations being tested in court. A lawsuit reflects what a plaintiff claims, not a final determination of liability, and the science connecting these drugs to gastroparesis is still developing.

What the science and regulators say

The evidence on GLP-1 drugs and the most serious gastrointestinal injuries is still developing and is not uniform. The U.S. Food and Drug Administration has documented gastrointestinal effects of these drugs and, in its Adverse Event Reporting System (FAERS) update covering April through June 2022, identified a potential signal of intestinal obstruction associated with GLP-1 receptor agonists. That signal is a closed one rather than an open inquiry: the same FAERS entry records that the Adverse Reactions section of the labeling was updated between November 2022 and September 2023 to include information about ileus. The prescribing information for Ozempic and related products now lists ileus and intestinal obstruction, along with severe constipation including fecal impaction, among adverse reactions reported during postmarketing use, and advises that the drug has not been studied in and is not recommended for patients with severe gastroparesis. At the same time, the FDA has not concluded that these drugs cause gastroparesis, and published studies have reached differing conclusions about the size of any increased risk. The presence of an adverse reaction on a drug label reflects reports received, not proof that the drug caused any particular case.

Note: Nothing here establishes that any GLP-1 drug causes gastroparesis or that any product caused any individual's illness. Regulators continue to study these effects, and the science may evolve.

The status of the GLP-1 litigation (as of June 2026)

Most federal GLP-1 cases are consolidated in In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen S. Marston. The Judicial Panel on Multidistrict Litigation created the MDL in February 2024 to handle claims alleging gastrointestinal injuries. According to JPML statistics, the number of pending federal actions in the MDL was in the several thousands in 2026, on the order of roughly 3,700 to 3,800 cases as of mid-2026, and the docket has continued to grow as new cases are filed. A separate MDL, No. 3163, was created in the same court for claims alleging a vision condition called non-arteritic anterior ischemic optic neuropathy (NAION). As of June 2026 the gastrointestinal litigation remains in pretrial proceedings, with general-causation expert discovery and rulings on whether the science supports the claims still ahead, and there is no settlement and no single universal resolution covering everyone who used these drugs.

Who may be involved

The people generally involved in this litigation are individuals who were prescribed and used a GLP-1 receptor agonist such as Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or Trulicity and were later diagnosed with a qualifying gastrointestinal injury, such as gastroparesis, ileus, or intestinal obstruction. Whether any particular person may have a claim depends on the specific facts, including which drug was used and for how long, the diagnosis and its timing, the medical record connecting the two, and the law of the relevant state. Use of one of these drugs alone does not establish a claim, and many people who take them experience only the common, milder side effects described on the label. Nothing here suggests that every patient has a claim or that any outcome is assured.

Deadlines and why they matter

Claims like these are subject to statutes of limitations, which are legal deadlines to file suit. These deadlines vary by state and by the type of claim, and many states measure the deadline from when a person knew or reasonably should have known that an injury may be linked to the product, a concept sometimes called the discovery rule. Because the deadline depends on your state and your facts, there is no single national filing deadline, and this page does not state any individual's deadline. Missing a deadline can permanently bar a claim, so people who believe they may be affected often act promptly rather than waiting. A licensed attorney in the relevant state can evaluate which deadline applies to a specific situation.

How to evaluate your options

If you are trying to understand your legal options, the appropriate step is to speak with a licensed attorney who handles this type of case. An attorney can assess the facts, explain the applicable law in your state, and advise whether you may have a claim; this page cannot do that. It can help to gather any records you have, such as proof of which GLP-1 drug you used and when, your prescription and pharmacy history, and your medical records confirming a gastrointestinal diagnosis and its date. Most mass tort and personal injury attorneys offer a free, confidential consultation, and many work on a contingency basis, meaning a fee is generally owed only if there is a recovery. A consultation creates no obligation to file.

Frequently Asked Questions

What is the Ozempic and GLP-1 lawsuit about?

It involves claims that GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity, caused severe gastrointestinal injuries such as gastroparesis (stomach paralysis), ileus, and intestinal obstruction, and that the manufacturers failed to warn adequately. The claims are brought as failure-to-warn and design-defect product liability cases under state law.

Is there a GLP-1 MDL, and what is the case number?

Yes. Most federal GLP-1 cases alleging gastrointestinal injuries are consolidated in In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen S. Marston. A separate proceeding, MDL No. 3163, handles vision-related claims.

Do Ozempic and other GLP-1 drugs cause stomach paralysis?

This is not settled. The FDA identified a potential signal of intestinal obstruction for GLP-1 receptor agonists in its April through June 2022 FAERS report, and the labeling was updated between November 2022 and September 2023 to add ileus, but the FDA has not concluded that these drugs cause gastroparesis, and studies have reached differing conclusions. A lawsuit is not proof of causation in any individual case.

Is there a settlement?

As of June 2026 there is no settlement in the GLP-1 gastrointestinal litigation. The cases are in early pretrial stages, with key rulings on the science still ahead. Litigation status can change, so confirm the current posture before relying on any figure, and be cautious of sources that promise a settlement amount.

Who qualifies to file a claim?

There is no automatic qualification. Whether a person may have a claim depends on the specific facts, including which GLP-1 drug was used and for how long, the gastrointestinal diagnosis, the medical record, and the law of the relevant state. A licensed attorney can evaluate eligibility.

How much are GLP-1 cases worth?

There is no guaranteed amount. The litigation is early, no settlement framework exists, and outcomes are uncertain. No one can promise a recovery or a dollar figure, and any value would depend on the specific facts and the eventual course of the litigation.

Is there a deadline to file?

Yes, but it varies. Statutes of limitations differ by state and by the type of claim, and many states measure the deadline from when a person reasonably should have connected an injury to the drug. There is no single national deadline, so the applicable one should be confirmed with an attorney in the relevant state.

Do I have to pay upfront?

Most mass tort and personal injury attorneys offer a free, confidential consultation and work on a contingency basis, meaning a fee is generally owed only if there is a recovery. Confirm the specific terms with any attorney you consult.